Lung Adenocarcinoma

This study identifies ERO1A as a novel and promising biomarker for early-stage lung adenocarcinoma (esLUAD). High ERO1A expression is associated with poor prognosis, yet paradoxically, it correlates with an immune-activated tumor microenvironment. Tumors with elevated ERO1A levels demonstrate a superior response to immune checkpoint inhibitors. This biomarker could therefore aid in patient stratification and guide peri-operative therapeutic decisions.

This study investigates histologic transformation to lung squamous cell carcinoma (LUSC) in EGFR-mutant lung adenocarcinoma (LUAD) patients, an underrecognized resistance mechanism. Multiomic analyses revealed that patients with transforming or adenosquamous (LUAS) phenotypes experienced shorter overall survival on first-line osimertinib. Inactivation of the retinoblastoma (Rb) pathway, particularly via CDKN2A/B deletions, was identified as a key driver of this transformation. Furthermore, MET pathway upregulation was observed, and combined EGFR and MET inhibition demonstrated efficacy in preclinical models. These findings suggest novel strategies to counteract this aggressive form of resistance.

This retrospective study investigated eight cases of multifocal micronodular pneumocyte hyperplasia (MMPH) associated with tuberous sclerosis complex (TSC), a rare benign pulmonary lesion. Patients typically presented with multiple ground-glass nodules in the lungs on CT scans and various clinical manifestations of TSC. A significant diagnostic challenge was highlighted, as intraoperative frozen sections were often misdiagnosed as early-stage lung adenocarcinoma. Next-generation sequencing revealed TSC1 or TSC2 gene mutations in most patients, confirming the association with TSC. All followed-up patients showed a favorable overall survival.

This prospective study evaluated gene expression profiling of seven genes (EGFR, FGFR2, PIK3CA, PTEN, SMAD4, STK11, TP53) in cell-free RNA (cfRNA) from exhaled breath condensate (EBC) in patients with advanced lung adenocarcinoma. Results indicated that PIK3CA showed the best diagnostic performance in distinguishing patients from healthy controls. High expression of FGFR2 and PIK3CA was associated with significantly shorter overall survival, highlighting their prognostic relevance. EGFR expression demonstrated a strong correlation between EBC and plasma, and low EGFR expression was linked to longer survival in patients receiving chemotherapy alone. This non-invasive EBC-based approach offers potential for molecular characterization and patient stratification.

This retrospective study analyzed 120 cases of lung adenocarcinoma (LUAD) with malignant serous effusions (MSE) to characterize their clinicopathologic, molecular, and prognostic features. Pleural effusions were most common, but pericardial involvement was associated with the shortest overall survival. Molecular profiling revealed TP53 mutations and actionable alterations in genes such as EGFR, KRAS, BRAF, ALK, and ROS1. NKX2-1 (TTF-1) negativity and the absence of actionable alterations were independent adverse prognostic factors, with dual NKX2-1/CD274 (PD-L1) negativity defining the poorest prognosis subgroup. Immunotherapy-based regimens and tyrosine kinase inhibitors showed varying survival benefits.

This study characterized the molecular architecture of the tumor microenvironment (TME) in lung adenocarcinoma (LUAD) with somatic BRCA1/2 mutations, using single-cell sequencing and multi-omics data. BRCA1/2 mutations are linked to increased genomic instability and poor prognosis, yet predict better clinical outcomes with immune checkpoint blockade (ICB) treatment. BRCA1 mutations correlate with an upregulated type I IFN/IFN-γ signature and CD8+ T cell activation, while BRCA2 mutations are associated with inflammatory responses and enhanced MHC-II antigen presentation, influencing CD4+ T cell differentiation. The study also identified tissue-resident memory T cell (Trm) subsets as predictors of ICB response and found that a cancer-promoting program activated by BRCA1 is vulnerable to histone deacetylase inhibitors.